AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TEVA

Sabag Mark sold $1.9M of TEVA

Sabag Mark (See "Remarks") sold 46,000 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $41.93 ($1.93M total) on 2026-11-05.

Original reporting
SEC EDGAR · Sabag Mark
Published Nov 6, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Bearish
medium confidence
Mentioned
$TEVA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVABearishLow
01

Why it matters

A 46,000‑share sale by an officer reduces his holding to ~81k shares, representing a modest stake reduction that may prompt short‑term price softness.

02

Market read

The filing provides fresh insider activity data, offering a small but actionable signal for TEVA traders.

03

What to watch

Potential tax planning or portfolio rebalancing reasons behind the sale.

Relevance 6/10Novelty 6/10Timing: after-market filing on 2026-11-06

Background

SEC Form 4 filings disclose insider transactions and are used by traders to gauge executive confidence.

Company-level read

Ticker impact

$TEVABearishMedium confidence
Context

Officer Mark Sabag sold 46,000 TEVA shares for $1.93M on 2026-11-05, reducing his stake to 80,760 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

Form 4 is a primary source; the transaction size is modest but the insider is an officer, which can influence short‑term sentiment.

Market effects

Sector

Minimal impact on the pharmaceutical sector; only a single insider transaction.

Regional

No broader regional effect.

Global

Limited to TEVA investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move and not indicative of future performance.

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd.

    Global generic drug manufacturer listed on NYSE.

  • Person
    Mark Sabag

    Officer of Teva who reported the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com